Mike Kagey

Mike Kagey has a strong background in the biomedical research and pharmaceutical industry. Mike worked as the Vice President of Translational Medicine at Leap Therapeutics, leading various roles in the company from 2016 onwards. Prior to that, they held positions as Senior Director of Translational Medicine, Director of Translational Research, and Associate Director of Research at Leap Therapeutics. Mike also gained experience in research and development at Tensha Therapeutics, which was later acquired by Roche. Before that, they worked as a Postdoctoral Fellow at the Whitehead Institute for Biomedical Research, where they focused on developing an imaging-based high throughput small hairpin RNA screen. Mike Kagey began their career as a Ph.D. student at the University of Virginia, where they identified and characterized the polycomb protein Pc2. Additionally, they co-founded and owned Crew Cut Landscape, a successful landscape company that operated for five years before being sold.

Mike Kagey earned a B.S. in Biochemistry and Cell Biology from Bucknell University, attending from 1996 to 2000. Mike later pursued a Ph.D. in Biochemistry and Molecular Genetics at the University of Virginia from 2000 to 2006.